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A B S T R A C T
Objective: To obtain practical experience with venlafaxine
for hot flushes in breast cancer patients and incorporate
this in a treatment protocol. 
Method: Twenty-two women with a history of breast cancer
(mean age 49.2 years, range 35-65) were referred for
consideration of treatment with venlafaxine for hot flushes.
Patients received extensive information on treatment with
venlafaxine and were advised to self-monitor the frequency
of their hot flushes. 
Results: Eight women did not start venlafaxine because they
had no postmenopausal complaints, were lost to follow-
up, had too low a frequency of hot flushes, or refused
treatment. Eventually 14 women started venlafaxine. Two
of them did not tolerate venlafaxine, four reported some
effect but stopped because of side effects, two women had
no effect whatsoever. Six women observed a clear (>50%)
reduction in their hot flush frequency that was main-
tained at a median follow-up of 13 months.
Conclusion: The group of patients referred for treatment
was more heterogeneous and more patients dropped out
because of side effects than expected. Extensive patient
education, patient selection and evaluation of the treatment
effect (by self-monitoring of hot flush frequency) are
mandatory to avoid useless (continuation of) treatment and
to prepare patients for side effects. Under these conditions, a
substantial minority of patients benefit from venlafaxine.
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I N T R O D U C T I O N
Hot flushes can be very bothersome postmenopausal
symptoms. In this phase of life, about 75% of women
experience hot flushes.1-3 Most prominent are attacks of
intense feelings of warmth, ascending from the chest to the
head and neck region. A hot flush lasts several minutes and
is accompanied by (often heavy and visible) transpiration
and reddening of the skin of the head and neck. Hot flushes
can also be accompanied by palpitations, dizziness, anxiety
and irritability.1
Some women have a couple of hot flushes a week, others
experience dozens a day. Also the intensity of hot flushes
can vary considerably. Hot flushes can easily lead to
avoidance of social contacts. Nightly hot flushes are especially
troublesome, resulting in awakening due to profuse
transpiration and having to change nightclothes and bed
sheets. The consequent interference with sleep easily leads
to daytime fatigue and diminished functioning. 
In women with breast cancer, menopause can occur as a
physiological phenomenon, but also as a side effect of the
(systemic) oncology treatment. Chemotherapy can induce
premature ovarian dysfunction, and in addition, hormonal
treatment with drugs such as tamoxifen and LH-RH-agonists
(‘chemical castration’) in hormone-sensitive breast cancer
can lead to frequent and annoying hot flushes.4 Bilateral
oophorectomy, if performed, equally results in an irreversible
postmenopausal state.
Temporary treatment with oestrogens is the most effective
treatment for hot flushes. In women without a history of
breast cancer, oestrogens provide a 50 to 100% reduction in
hot flush frequency.1,5 However, in patients with a history
of breast cancer, oestrogens are relatively contraindicated.
This is certainly the case for patients with hormone-sensitive
tumours, because oestrogens can stimulate the growth of
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‘microscopic’ tumour cells that might still be present after
surgery, radiotherapy and/or chemotherapy.6,7 In addition,
specifically in hormone-sensitive tumours, hormonal
manipulations aim to knock out the production of oestro-
gens or to block the stimulatory effects of oestrogens on
the tumour cell.
Until recently, only moderately effective alternatives for
treatment of hot flushes were available for this patient
group. With clonidine (Catapresan®, Dixarit®), for instance,
a drug that affects the central noradrenergic neurotrans-
mission and that in higher doses is used for the treatment
of hypertension and migraine, 10 to 20% reduction in
flushes are found as compared with placebo. This is a
modest effect, taking into account the possible side effects
as sedation, sleep disturbance, gastrointestinal symptoms
and hypotension.4,8
Over the past years, however, favourable results have been
reported with several modern antidepressants in women
with a history of breast cancer, at first with venlafaxine
(Efexor®), later on with fluoxetine (Prozac®) and paroxetine
(Seroxat®).9-11 In a randomised, placebo-controlled trial in
221 women with either a history of breast cancer or reluc-
tance to take hormones because of fear of breast cancer,
venlafaxine 75 mg daily resulted in a 61% reduction in
the hot flush scores (number of hot flushes/24 hours x
intensity), a response that was twice as high as in the
placebo group.9 A daily dose of 37.5 mg was somewhat
less effective, a dose of 150 mg was as effective as 75 mg
but induced more side effects.9 Recently, paroxetine was
also reported to be effective against hot flushes in healthy
women.12 The effects on hot flushes of these serotonergic
drugs are thought to be mediated by an influence on a
complex interaction of serotonin, noradrenaline, gonado-
tropic hormones and sex hormones in the thermoregulatory
centres of the brain.12,13
After the publication by Loprinzi et al. in 2000, the oncology
staff of our hospital decided to refer breast cancer patients
with troublesome hot flushes to the psychiatry service in
order to concentrate the experience with venlafaxine for this
indication. At that time, we were unsure of the generalis-
ability of the findings. In addition, the psychiatrists were
familiar with venlafaxine and its side effects. The aim was
to incorporate this clinical experience, finally, in a protocol
or checklist. 
P A T I E N T S  A N D  M E T H O D S
From January 2001 until July 2003, 22 women (mean age
49.2 years, range 35-65, SD 7.8) with a history of breast
cancer were referred to the psychiatry department for
possible treatment with venlafaxine for hot flushes. No
strict referral criteria were established: obviously, patients
had to be burdened significantly by hot flushes.
Pretreatment with clonidine was advised. A semistructured
history was taken and patient information was given
according to table 1. For five days prior to starting venlafax-
ine, the patients monitored the frequency of troublesome
hot flushes on a registration sheet (for each night, morning,
afternoon, and evening). The decision to start venlafaxine
Van Gool, et al. Venlafaxine for hot flushes in breast cancer patients.
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Table 1
Items to be addressed in breast cancer patients when prescribing venlafaxine for hot flushes
INFORMATION
No registration for this indication; few data on long-term efficacy
Most frequently occurring side effects: agitation, anxiety, gastric symptoms, constipation, dry mouth
May influence driving ability (warning on package)
Side effects manifest first, positive effects on hot flushes later
Venlafaxine only influences hot flushes, not other menopausal complaints as vaginal dryness or osteoporosis, nor does it have a direct 
positive effect on joint pains, fatigue, concentration difficulties
Effect to be expected is a reduction of 50% or more in hot flush frequency, according to literature data, intensity of flushes can also decrease 
Explanation of rationale for self-monitoring of hot flush frequency: avoiding unnecessary treatment, enabling evaluation of the effect of 
therapy and of the ratio of benefits over side effects
INDICATION FOR PSYCHIATRIC REFERRAL, (RELATIVE) CONTRAINDICATIONS FOR VENLAFAXINE
Previous experience (side effects!) with serotonergic antidepressants (fluvoxamine-Fevarin®, fluoxetine-Prozac®, paroxetine-Seroxat®, 
sertraline-Zoloft®, citalopram-Cipram®)
Depressed now? Have you been consistently depressed or down, most of the day, nearly every day, for the past two weeks? In the past two weeks,
have you been less interested in most things or less able to enjoy the things you used to enjoy most of the time?
History of manic episode(s)? Have you ever had a period of time when you were feeling, ‘up’ or ‘high’ or so full of energy or full of yourself 
that you got into trouble, or that other people thought you were not your usual self? Do not count times when you were intoxicated by 
drugs or alcohol. Have you ever been persistently irritable, for several days, so that you had arguments or verbal or physical fights, or 
shouted at people outside your family? Have you or others noticed that you have been more irritable or overreacted, compared with other 
people, even in situations that you felt were justified? 
Anxiety disorder? Easily worried and tense? Sudden attacks of anxiety? Avoidance of places and situations in which you could become anxious
or panicky? Compulsive behaviour as excessive checking or washing hands?
was made by the patient and the psychiatrist together; a
threshold frequency of hot flushes for starting venlafaxine
was not required. Follow-up visits were arranged after two
to three weeks, four to six weeks and four to six months.
Before each follow-up visit, the women monitored the
frequency of troublesome hot flushes for a period of two
to three days. Some of these follow-up appointments took
place by telephone, e-mail or fax. The starting daily dose
of venlafaxine was 75 mg, after two or three weeks, the
dose could be increased to 150 mg in case of insufficient
effect. We did not use predetermined criteria for response:
the decision to stop or to continue venlafaxine after four
to six weeks (or earlier in case of side effects) was taken
after the patient and psychiatrist had discussed the costs
and benefits.
R E S U L T S
At the first visit to the psychiatrist (AVG), one woman had
complaints which could not be regarded as hot flushes
and not even as postmenopausal. She was not prescribed
venlafaxine. Of the remaining 21 patients, the hot flushes
were attributed to the physiological menopause in two
women, and in 19 to previous or ongoing treatment for
breast cancer. Fourteen women had previously been treated
with clonidine for hot flushes. For one woman, no reliable
self-monitoring could be obtained; she was lost to follow-up.
At self-monitoring, the frequencies of hot flushes turned
out to be rather variable. In six cases it was decided not to
start with venlafaxine. In three of these six women, to their
own surprise, the hot flush frequency at self-monitoring
was considerably lower than previously perceived by them.
After receiving information, three women declined treat-
ment, mainly because of a reluctance to use more drugs
than they were already taking and a reluctance to take a
‘psychiatric’ drug. One patient had a depressive syndrome,
of mild intensity (score on the Zung self-rating scale for
depression: 49). Problems at work and sleep disturbance
because of nightly hot flushes (with resulting daytime
fatigue and irritability) were thought to be causal factors
in this depression. 
Eventually, 14 women (mean age 48.5 years, range 42-59,
SD 6.0) started venlafaxine. In one of these women the
hot flushes were attributed to the physiological
menopause, in the other 13 to previous or ongoing treatment
for breast cancer (hormonal therapy in eight, chemotherapy
in one, combination of hormonal and chemotherapy in
four). The reported duration of annoying hot flushes was
more than two years in eight women, between six months
and two years in four, and less than six months in two.
On self-monitoring, ten women recorded between 10 and
25 hot flushes per 24 hours, while four women recorded
more than 25. Ten women had been treated with clonidine. 
One patient insisted on continuing clonidine, and venlafax-
ine was added. Two women did not tolerate the starting
dose of 75 mg venlafaxine because of severe agitation,
anxiety and profound malaise occurring in the hours after
taking the first dose. In four women, venlafaxine was
effective to some extent (30 to 50% decrease in hot flush
frequency), but they stopped taking venlafaxine because
of troublesome side effects as constipation, weight gain
and sleep disturbance. In two women, venlafaxine had no
effect at all in doses of 75 and 150 mg respectively. 
Six women took venlafaxine for three months or longer
(four women in a daily dose of 75 mg, and two in a dose
of 150 mg) and experienced a more than 50% reduction
in hot flush frequency without significant side effects. In
two of them, the hot flushes disappeared completely.
Two women reported a definite psychic alteration: in the
above-mentioned depressive patient, the depression went
into remission; the other woman reported feeling less
irritable and more able to cope emotionally with her
difficulties. In these six women, the effect was maintained
in the long term: dose increase was not necessary during
a median follow-up of 13 months (range: 5-36 months). 
D I S C U S S I O N
The group of breast cancer patients referred for treatment of
hot flushes was more heterogeneous than expected in terms
of the frequency (and in one patient even the presence) of
hot flushes and in terms of subjective burden. After self-
monitoring, some women turned out to have far less
flushes than had thought beforehand. Others decided
against treatment after receiving information. Presumably,
aside from their reluctance to take more or ‘psychiatric’
drugs, knowing that a form of treatment would be available
if the symptoms became more intense satisfied these
patients. Patient selection by giving extensive patient
information, a standardised history (table 1) and self-
monitoring of the hot flush frequency appears to prevent
unnecessary treatment in majority of patients. 
Of the treated patients, quite a lot dropped out because of
side effects. Two patients even became severely agitated after
the first dose. Patient education, in this way, is obviously
also useful to prepare patients for annoying or even
frightening side effects. Furthermore, evaluation of the
treatment effect by means of self-monitoring is mandatory
to avoid useless continuation of treatment. We noticed in
several patients that clonidine had been prescribed for
longer periods without much evidence of a positive effect.
Evaluation of the treatment turned out to also be useful
in enabling the patients to weigh the beneficial effects on
the hot flushes against the side effects and the necessity to
take another medication. In a context of extensive patient
education, standardised history taking and self-monitoring,
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more than one third of patients appear to derive a long-term
benefit from venlafaxine.
The number of referrals was unexpectedly low. According
to the oncology staff, women were mainly reluctant to
take more drugs. In addition, a referral to a psychiatrist,
for a possible treatment with a psychotropic drug, could
have been an obstacle. 
We realise that the procedure as presented here is relatively
laborious. However, specialised oncology or psychiatry
nurses could assist in patient education and self-monitoring.
Moreover, as most oncologists will not be confronted
frequently enough with this problem to build up experience,
a standardised history as shown in table 1 could be useful.
In addition, it is important to obtain a short psychiatric
history. For instance, in patients who went through a
manic episode earlier in their life antidepressants might
provoke a recurrent mania. Patients who had previously
been treated with a serotonergic antidepressant should be
asked about side effects: logically, they could experience
the same side effects again. It is important to assess the
presence of an ongoing mood or anxiety disorder.
Questions on depression and a history of manic episodes
can be asked directly or, as shown in table 1, with modules
of the M.I.N.I.14 Screening on depression and anxiety can
also be done with self-report questionnaires as the Hospital
Depression and Anxiety Scale.15 If a mood or anxiety
disorder is suspected, consulting with a psychiatrist or
the general practitioner is self-evident. 
Finally, we believe that our clinical experience in breast
cancer patients is also relevant for the treatment of hot
flushes in general (as part of the physiological menopause
in otherwise healthy women), especially since long-term
hormone replacement therapy in women with menopausal
symptoms is under debate.16
According to the literature, venlafaxine is an effective therapy
for hot flushes in breast cancer patients. Our experience
indicates that matters are more complex and that the best
results with this drug are obtained with extensive patient
information, patient selection and repeated evaluation of
the effects by self-monitoring of hot flush frequency.
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